---
document_datetime: 2025-01-09 16:54:14
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bimzelx-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: bimzelx-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.1161
conversion_datetime: 2025-12-22 01:02:45.290518
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Bimzelx

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                              |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------|
| IA/0032              | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 19/12/2024                          | n/a                                         |                                  |                                                                                                                      |
| II/0028              | Update of section 5.1 of the SmPC in order to update efficacy information based on the final results from                            | 12/12/2024                          |                                             | SmPC and PL                      | At week 48, patients were allowed to enter a 96-week open label extension period (OLE) and started or continued with |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | study PS0015 listed as a category 3 study in the RMP; this is a multicenter, randomised, double-blind, secukinumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis. In addition, the MAH has taken the opportunity to update the list of local representatives in the Package leaflet and align the PI with the latest QRD template version 10.4 as well as to update wording on polysorbates in the SmPC and the Package leaflet to align with the annex of the guideline related to excipients. The RMP version 3 is acceptable. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | bimekizumab 320 mg Q4W or 320 mg Q8W depending on their PASI 90 responder status at week 48. Study participants who initially received bimekizumab 320 mg Q4W during the OLE were switched to bimekizumab 320 mg Q8W at week 72 or later. Among the patients remaining in the study, improvements achieved with bimekizumab or secukinumab for the efficacy endpoints PASI 100, PASI 90, PASI 75 and PASI ≤2 responder at week 48 were maintained on treatment with bimekizumab 320 mg Q8W through an additional 96 weeks of open label treatment. The safety profile of bimekizumab up to week 144 was consistent with the safety profile observed up to 48 weeks. For more information, please refer to the Summary of Product Characteristics.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029 | Submission of the final report from study PS0014 (BE BRIGHT) listed as a category 3 study in the RMP. This is a multicenter, open-label extension (OLE) study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult study participants with moderate to severe plaque PSO who completed 1 of the 3 completed feeder studies. The RMP version 2.3 is considered acceptable. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission                                                                                                                                                                                                                                               | 31/10/2024 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| PSUSA/10953 /202402   | Periodic Safety Update EU Single assessment - bimekizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 03/10/2024   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0030               | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 01/10/2024   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| X/0021                | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 30/05/2024   | 01/08/2024 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0027               | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 17/05/2024   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0025               | Update of section 5.1 of the SmPC in order to add long-term efficacy data based on the interim results (week 144 data) from study PS0014 listed as a category 3 study in the RMP; this is an ongoing, multicenter, open-label extension (OLE) study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult study participants with moderate to severe plaque PSO who completed 1 of the 3 completed feeder studies (PS0008, PS0009, and PS0013). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 16/05/2024   | 01/08/2024 | SmPC                   | Patients who completed one of the pivotal phase 3 studies ('feeder studies') could enter a 144-week open-label extension study (PS0014) to assess the long-term safety and efficacy of bimekizumab. 344 patients who were treated with bimekizumab 320 mg every 8 weeks (BKZ 320 mg Q8W) or every 4 weeks (BKZ 320 mg Q4W) during the feeder study, and who achieved PASI 90 at the end of the feeder study, received bimekizumab 320 mg Q8W throughout PS0014. Of these, 293 (85.2%) patients completed 144 weeks of treatment with bimekizumab 320 mg Q8W. 48 patients (14.0%) discontinued the study during the treatment period, of which 21 (6.1%) discontinued due to an adverse event and 4 (1.2%) discontinued due to lack of efficacy. Among the patients remaining in the study, improvements achieved with bimekizumab for the efficacy endpoints PASI 90 and IGA 0/1 in the feeder studies were maintained through an additional 144 weeks of open-label treatment. |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             | For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------|
| II/0020             | Extension of indication to include treatment of moderate to severe hidradenitis suppurativa (HS) in adults, based on final results from study HS0003 (BE HEARD I) and study HS0004 (BE HEARD II). These are phase 3, randomised, double blind, placebo controlled, multicenter, pivotal studies evaluating the efficacy and safety of bimekizumab in study participants with moderate to severe HS. Further supportive data are based on the results of phase 2 study HS0001 and phase 3 currently ongoing open- label extension study HS0005. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package leaflet is updated in accordance. RMP version 1.12 is acceptable. Furthermore, the PI is brought in line with the latest QRD template version 10.3. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 21/03/2024 | 19/04/2024 | SmPC and PL | Please refer to Scientific Discussion 'Bimzelx-H-C-005316- II-Var.0020'.        |
| PSUSA/10953 /202308 | Periodic Safety Update EU Single assessment - bimekizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 07/03/2024 | n/a        |             | PRAC Recommendation - maintenance                                               |
| II/0023/G           | This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 14/12/2023 | n/a        |             |                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | control/testing takes place and any of the test method at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                                                                                                                                                               |            |            |             |                                                                          |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------|
| IB/0022             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 09/11/2023 | 19/04/2024 | SmPC and PL |                                                                          |
| PSUSA/10953 /202302 | Periodic Safety Update EU Single assessment - bimekizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 28/09/2023 | n/a        |             | PRAC Recommendation - maintenance                                        |
| IB/0019             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/06/2023 | n/a        |             |                                                                          |
| II/0011             | Extension of indication to include treatment of active psoriatic arthritis in adults patients who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) for Bimzelx, based on results of a Phase III study in biological DMARD naïve study participants (PA0010; BE OPTIMAL) and a Phase III study in study participants who are inadequate responders (inadequate response or intolerant) to ≤2 prior TNF inhibitors (PA0011; BE COMPLETE). Both Phase III studies are interventional studies aimed to evaluate the efficacy and safety of bimekizumab. For | 26/04/2023 | 05/06/2023 | SmPC and PL | Please refer to Scientific Discussion 'Bimzelx-H-C-005316- II-Var.0011'. |

<div style=\"page-break-after: always\"></div>

|         | and no inferential active reference (adalimumab)- controlled, while PA0011 was placebo-controlled. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 to the SmPC have been updated. The Package leaflet is updated in accordance. The RMP version 1.7 is acceptable. Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev.1. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                               |            |            |             |                                                                          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------|
| II/0010 | Extension of indication to include treatment of adults with active axial spondyloarthritis (axSpA), including non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS, radiographic axial spondyloarthritis), based on results from two interventional and controlled phase III clinical studies: AS0010 (BE MOBILE 1) and AS0011 (BE MOBILE 2), which provide evidence of the efficacy and safety of bimekizumab in axSpA (nr-axSpA and AS), both compared to placebo treatment. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package leaflet is updated in accordance. The RMP version 1.8 is acceptable. Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev.1. | 26/04/2023 | 05/06/2023 | SmPC and PL | Please refer to Scientific Discussion 'Bimzelx-H-C-005316- II-Var.0010'. |

<div style=\"page-break-after: always\"></div>

|                     | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                      |            |            |             |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IA/0017/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 26/04/2023 | n/a        |             |                                   |
| PSUSA/10953 /202208 | Periodic Safety Update EU Single assessment - bimekizumab                                                                                                                                                                                                                                           | 16/03/2023 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0016             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                    | 15/03/2023 | n/a        |             |                                   |
| IB/0015             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                | 09/01/2023 | n/a        |             |                                   |
| IB/0013             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                      | 05/12/2022 | 31/05/2023 | SmPC and PL |                                   |
| IB/0012             | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                           | 21/10/2022 | n/a        |             |                                   |
| PSUSA/10953 /202202 | Periodic Safety Update EU Single assessment - bimekizumab                                                                                                                                                                                                                                           | 29/09/2022 | n/a        |             | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0009   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                                                                                                                                                                                                                                             | 25/08/2022   | n/a        |                        | variation             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------|
| IB/0006   | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                           | 19/08/2022   | n/a        |                        |                       |
| IB/0008/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 29/07/2022   | n/a        |                        | batch control/testing |
| IB/0007   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                 | 27/06/2022   | n/a        |                        |                       |
| II/0003/G | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting                                                                                                                                                                                                                                                                                            | 19/05/2022   | 31/05/2023 | Annex II and Labelling |                       |

<div style=\"page-break-after: always\"></div>

|         | material [-] used in the manufacture of a biological/immunological product B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002 | Update of section 5.1 of the SmPC in order to update efficacy information based on interim results from study PS0015; this is a multicenter, randomized, double-blind, active comparator controlled, parallel group study to evaluate the efficacy and safety of bimekizumab compared with secukinumab in adult study participants with moderate to severe plaque psoriasis. In addition, the MAH took the opportunity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/03/2022 | 31/05/2023 | SmPC, Annex II and PL | The efficacy and safety of bimekizumab was evaluated in a double-blind study compared with secukinumab, an IL-17A inhibitor. Bimekizumab-treated patients achieved significantly higher response rates compared to secukinumab. The results are consistent with the previous pivotal study results previously assessed and reported in the SmPC. For more information, please refer to the |

<div style=\"page-break-after: always\"></div>

|         | to bring the PI in line with the latest QRD template version 10.2. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | Summary of Product Characteristics.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------|
| II/0004 | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                  | 10/03/2022 | n/a |                                       |
| IB/0001 | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                             | 11/10/2021 | n/a |                                       |